Cambridge researchers are harnessing the latest developments in science and technology to help us predict, diagnose and treat cancers at an ever earlier stage.
Med-tech start-up 52 North Health has raised £1 million in its first round of funding to help it develop the NeutroCheck, a fully-integrated clinical...
Marcel Gehrung, co-founder and CEO of rapidly growing Cambridge biotech company, Cyted, on revolutionising disease diagnostics and the challenges of...